All the Resources You Need -- At Your Fingertips
Help your patients develop a comprehensive Seizure Preparedness Plan, download patient education materials and hear real physicians discuss their experience with DIASTAT AcuDial. Enter resource center.
Help your patients develop a comprehensive Seizure Preparedness Plan, download patient education materials and hear real physicians discuss their experience with DIASTAT AcuDial. Enter resource center.
About DIASTAT® AcuDial™ (diazepam rectal gel)
DIASTAT AcuDial is a gel formulation of diazepam intended for rectal administration in the management of selected, refractory patients over age 2 with epilepsy, on stable regimens of AEDs, who require intermittent use of diazepam to control bouts of increased seizure activity1.DIASTAT AcuDial provides a range of dosing capabilities to meet the needs of a specific individual patient in a single administration.
DIASTAT AcuDial contains the same diazepam rectal gel used in the original product.
Read more about:
Reference:
- DIASTAT AcuDial package insert. Aliso Viejo,Calif: Valeant Pharmaceuticals NA; Nov 2006.
IMPORTANT SAFETY INFORMATION
DIASTAT® AcuDial™ (diazepam rectal gel) is a gel formulation of diazepam intended for rectal administration in the management of selected, refractory patients with epilepsy, on stable regimens of AEDs, who require intermittent use of diazepam to control bouts of increased seizure activity for patients 2 years and older.
In clinical trials with DIASTAT®, the most frequent side effect was somnolence (23%). Less frequent adverse events reported were dizziness, headache, pain, vasodilation, diarrhea, ataxia, euphoria, incoordination, asthma, rash, abdominal pain, nervousness and rhinitis (1%-5%). Please see full DIASTAT AcuDial Prescribing Information.
DIASTAT® AcuDial™ (diazepam rectal gel) is a gel formulation of diazepam intended for rectal administration in the management of selected, refractory patients with epilepsy, on stable regimens of AEDs, who require intermittent use of diazepam to control bouts of increased seizure activity for patients 2 years and older.
In clinical trials with DIASTAT®, the most frequent side effect was somnolence (23%). Less frequent adverse events reported were dizziness, headache, pain, vasodilation, diarrhea, ataxia, euphoria, incoordination, asthma, rash, abdominal pain, nervousness and rhinitis (1%-5%). Please see full DIASTAT AcuDial Prescribing Information.
© Valeant Pharmaceuticals North America 2007
Legal and Privacy Statement
DIASTAT® AcuDial™ is a registered trademark of Valeant Pharmaceuticals North America. D896-0607 Site Map